Tristan Jervis is the founder and Managing Director of Impact Shine Communications.

He leads a team of skilled life science and healthcare industry communications practitioners at Impact Shine communications to support and service organisations with bespoke UK, pan-European, US and international strategic PR communications, marketing communications, Government Relations, Public Affairs and Investor Relations programmes.

He has a 20-year pedigree – in part acquired at three previous agencies – in servicing companies with strategic communications needs in life science & healthcare sectors ranging across pharmaceuticals, biopharmaceuticals, medical technology and devices, diagnostics, biotechnology, specialist tools and technology services, CDMOs, clinical and pre-clinical research and consumer health.

He has directed and co-directed strategic communications campaigns – including public affairs – across the industry spectrum for companies ranging from start-ups, through to smaller SMEs such as Aerte (Inov8 Sciences), through to medium sized entities such as ALOKA (acquired by Hitachi Medical), through to large companies such as Envigo (partially acquired by LabCorp Covance) and industry giants including Novartis, Abbott Laboratories, Dade Behring (acquired by Siemens) and Johnson & Johnson.

He has serviced industry brands including Recipharm, Bespak, Aesica Pharmaceuticals (acquired by Consort Medical/Recipharm), The Almac Group, Synco BioPartners, Cobra Biologics, Symcel, Andor (acquired by Oxford Instruments), Evotec, bioMérieux, Vivacta (acquired by Novartis), Domainex, Plasticell, Progenitor Laboratories, Olympus, VisualSonics (Fujifilm Sonosite), Exco InTouch (acquired by ERT), Plant Impact (acquired by Croda), Applied Cytometry and the Cancer Relief MacMillan Fund.

Dr Sarah Harding is a Senior Director at Impact Shine Communications. She heads up the agency’s specialist writing unit.

Sarah is a Life Science and Healthcare/Medical Communications specialist with 25+ years’ experience in the pharmaceuticals and speciality chemicals sectors. With a passion for strategic thought leadership initiatives, her skills encompass directing communications planning, technical and scientific writing and editing of articles, White Papers and case studies, project management and opinion-leader development.

Dr Harding has a well-established pedigree as a medical writer and senior consultant in the pharmaceutical industry. She also has an accomplished publishing background – having served as a former Editorial Director at Chemicals Knowledge and Editor at Speciality Chemicals Magazine and currently editing the Annual Where To Buy Chemicals Directory.

Laura Air is the Internal Communications and Consumer Comms Director at Impact Shine Communications.

Laura is a seasoned, senior communications consultant with over 20 years of acquired expertise.

She has developed internal and external communication strategies for world-renowned organisations, represented global brands and advised on challenges from embedding new vision and values to delivering against ED&I objectives. She is skilled at developing and adapting messaging for specific audiences and creating impactful content with defined purpose.  She also has experience of designing and implementing highly successful change communication programmes.

Laura’s past clients have included KPMG, Unilever, Johnson Matthey, Pharmaron and Australian Pharmaceutical Industries.

Stuart Wakelin, PhD, is the Medical Communications and Life Science Director at Impact Shine Communications.

He has over 16 years’ experience in providing high-level scientific communications for global pharma in a wide variety of fields, including (but not exclusive to) respiratory diseases, cardiovascular disease, cardiology and haematology, dermatology, oncology, ophthalmology, endocrinology and metabolism, infectious diseases, neurology and surgical and diagnostic devices. Previous roles and responsibilities include acting as Scientific Director for a large Medical Communications agency, the training and the oversight of multiple teams of scientific writers, and Scientific Delivery Team Lead for GSK’s Ellipta approval and launch publications programme. Stuart has worked on many accounts with many of the world-leading pharma companies, including Alcon (Vivity, Ngenuity), AstraZeneca (Tezspire), BMS (apixaban), GSK (Ellipta, dostarlimab), Novartis (Exelon, Promacta), Pfizer (Vydura), and Sanofi (Plavix), as well as global organisations such as FIND, and Oxford University.

While Stuart specialises in peer-reviewed publications, he has also worked closely with pharma on a variety of activities, including digital platform content, meeting and symposia activities, Investigator brochures, protocols, clinical study reports, and other medical education and regulatory documents. Recently, his work has focussed on precision medicine in oncology, specialising in targeted therapies, and support with early-phase drug development communications.

Adam Michael is a Specialist Corporate, Financial Communications and Investor Relations Consultant at Impact Shine Communications.

He has nearly 30 years expertise in servicing life science biotech, diagnostics and pharmaceutical companies in corporate, financial communications and investor relations for both public and private companies. His expertise includes private equity fundraising, taking companies through the IPO process to a stock market listing. His expertise encompasses devising financial messaging geared to investors and establishing elevator pitches that capture the essence of the investment proposition. He has devised strategies that guide companies through the entire process of raising private equity finance and preparing for stock market listings.

He has worked for a range of small, medium sized and larger sized private and publicly quoted entities, including directing the communications for an exclusive portfolio of clients at C-suite level. Clients serviced to date have included the likes of Roche / Genentech, Avacta, and AM-Pharma. Adam is also Director of Communications and Investor Relations at Ambrose Healthcare, a start-up pharmaceutical company in the rare disease space.

Adam was the European News Editor on BioCentury.

Matthew Gould is Impact Shine Communications Senior Design Consultant. He is a specialist in the healthcare and life sciences sectors.

Matthew handles graphic design tasks including advertisements, corporate/brand identity, website design and website enhancement, annual reports through to brochures, flyers, stands and stationery.
To date, Matthew has a 25 year pedigree of providing specialist design service support to pharmaceutical, medical device and technology and life science companies including Agilent, DXS, Roche Diagnostics, Synco BioPartners, Nikon, Johnson & Johnson, Roslin Institute, CAMR Porton Down, Genzyme, UCB Pharma, Axis-Shield Diagnostics, Oxford Instruments and WuXi Corporate.

James Harding is Web Services Director at Impact Shine Communications.

James is a seasoned expert in the provision of web services – having serviced clients in multiple sectors over a twenty year tenure. He has substantial web services expertise in the healthcare and life sciences arena, having designed technical user-friendly applications for multiple blue-chip pharmaceutical companies as an integral component within integrated medical, scientific and strategic communications campaigns.

He has also applied his technical skills in strategic public affairs campaigns. He developed the software for the successful pilot scheme that led to the UK Government introducing Tenancy Deposit Protection in 2007 and oversaw the development of a national database for a Government Carbon Emissions Reduction Target (CERT) scheme.

His practical approach means that he can explain technical concepts in straightforward plain English, with the skills and experience to ensure that your online presence functions in a positive manner and adds value to your organisation’s messaging.